# Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

> **NCT04880616** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 31 (actual)

## Conditions studied

- Essential Tremor

## Interventions

- **DRUG:** NBI-827104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04880616
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2022-05-25
- **Final completion:** 2022-06-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880616, "Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04880616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*